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(2001-2012) of 65 HSCT patients with myeloid malignan-
cies (n¼ 32), lymphoid malignancies (n¼27) or CML (n¼6)
who received DLI post-transplant to treat mixed chimerism
(MC, n¼15), minimal residual disease (MRD, n¼15) or
relapsed disease (RD, n¼35). Patients had received trans-
plants from related (n¼20) including haploidentical (n¼26),
unrelated (n¼35) or cord blood (n¼1) donors. Forty-two
patients received total body irradiation (TBI) and cyclo-
phosphamide-based conditioning while 16 received
busulfan and cyclophosphamide-based regimens. Twenty-
seven patients received conditioning with other chemo-
therapies  TBI. MC was deﬁned as evidence of recipient
cells on whole blood or bone marrow analysis using ﬂuo-
rescence in-situ hybridization (FISH) or short tandem
repeats. Nine of the 15 MC patients who received DLI did so
after the discontinuation (median of 35 days, range 1-217)
of graft versus host disease (GvHD) prophylaxis, while the 6
remaining DLI recipients had not been on prophylactic
therapy. MRD was deﬁned as the detection of a clone 
0.01% using polymerase chain reaction or FISH. Relapse was
deﬁned as any patient with a  5% blast population
detected in peripheral blood and conﬁrmed by microscopic
or ﬂow cytometric analysis. As a group, 26/65 patients are
alive after receiving DLI with a median follow-up of 24
months (range 3-102). Of patients with MC, 9/15 remained
in remission for a median of 22 months (range 3-85) with
7/15 experiencing Grade II-IV aGvHD. Of patients with
MRD, 12/15 remained in remission for a median of 77
months (range 5-102) with 5/15 experiencing grade II-IV
aGvHD. Eight of these 12 surviving patients were Phila-
delphia chromosome-positive. Of patients with RD, 5/36
remain alive with 3/5 in remission for a median of 43
months (range 4-63). 11/31 patients who expired experi-
enced Grade II-IV aGvHD. Hence, DLI may beneﬁt pediatric
myeloid and lymphoid malignancy patients post-HSCT with
MC and MRD (especially those with Philadelphia chromo-
some-positive leukemia). However, DLIs produced remis-
sion in only 3/36 patients with RD and the associated risk
of signiﬁcant GvHD likely worsens quality of remaining life
in the non-responders.167
Towards the Development of a Closed, Nanoﬁber-Based
Culture System for Clinical Expansion of Cord Blood
CD34+ Cells
Stephen E. Fischer, Yukang Zhao, Anirudhasingh Sodha,
Caitlin Smith, Yiwei Ma. Research & Development, Arteriocyte,
Inc, Cleveland, OH
Interest in ex vivo hematopoietic stem and progenitor cell
(HSPC) expansion has increased in recent years due to the
growing importance of these cells in the treatment of
a variety of both malignant and non-malignant diseases. Ex
vivo expansion of cord blood-derived cells has been partic-
ularly investigated because cord is a valuable and readily
available source of HSPCs, yet contains limited numbers of
cells in each unit. Despite these efforts, most attempts to use
expanded cord blood HSPCs in the clinic have been unsuc-
cessful due to the generation of insufﬁcient numbers of cells
with the appropriate phenotype and the ability to function in
vivo.
In many ex vivo culture systems, HSPCs are cultured as
a suspension cells and cultured in the presence of various
media additives that act to enhance cell proliferation while
reducing differentiation. An often-overlooked factorinﬂuencing fate decisions is the interaction of HSPCs with
a substrate. In the natural bone marrow microenvironment,
HSPCs maintain close contact with a complex network of
stromal cells and extracellular matrix, likely indicating that
cell-cell and cell-matrix interactions play an important role
in maintaining their stem cell phenotype. With the goal of
mimicking the bone marrow stem cell niche, Arteriocyte,
Inc. has developed a 3-D nanoﬁber-based cell culture
substrate. The functionalized nanoﬁber substrate is
designed to provide topographical and substrate-immobi-
lized biochemical cues that act in synergy with media
additives to enhance HSPC proliferation while minimizing
differentiation.
Here, we present our recent work towards developing
a closed, nanoﬁber-based platform for large-scale clinical
expansions of cord blood-derived CD34+ cells. We demon-
strate that our nanoﬁber substrate expands CD34+ cells from
cord an average of more than 150-fold in 10 day culture,
which is at least 2-fold higher than that obtained in standard
tissue culture plates. Additionally, we show an approxi-
mately 1.5-fold higher proliferation of colony forming cells
and a signiﬁcantly higher engraftment rate in NSG mice for
nanoﬁber-expanded cells compared to cells cultured in
tissue culture plates. Furthermore, we demonstrate that our
nanoﬁber scaffold maintains its HSPC growth promoting
characteristics after processing into a closed culture system
and offers signiﬁcant advantages over other culture plat-
forms typically used for HSPC expansions in the clinic
(culture bags and T-ﬂasks). Our data indicates that nanoﬁber
technology provides a robust ex vivo expansion of cord blood
HSPCs and, with further development, offers great potential
for clinical applications requiring large numbers of func-
tional cells.168
A Novel Process Technology for Automated NK Cell
Culture and Enrichment
Markus Granzin, Mareke Brüning, Iris Spiegel, Sabine Mueller,
Jessica Blaschke, Volker Huppert, Juergen Schmitz. Miltenyi
Biotec GmbH
Natural killer (NK) cells are a promising tool for cancer
therapy due to their ability to detect and eliminate cancer
cells. Using NK cells for therapeutic cell transfer in the
clinic requires high numbers of these cells. Therefore
a method for automated expansion of human NK cells is
developed.
Automation of NK cell expansion was done by use of the
CliniMACS Prodigy instrument, a novel technology for cell
processing in a clinical environment. Automated Ficoll
density gradient centrifugation was performed to remove
erythrocytes and granulocytes from buffy coat samples of
healthy donors and to obtain peripheral blood mononuclear
cells (PBMC). This automated method yielded a suitable
number of PBMC and a better depletion of granulocytes
compared to the manual PBMC preparation. PBMC were
cultivated with IL-2 and OKT-3 leading to an expansion of NK
cells, but also of NK like Tcells and Tcells. NK cell numbers up
to 5,1x108were reached with expansion factors of 54-208-
fold after three weeks. NK cell purities of 5-52% were
obtained.
Pure NK preparations are preferred with regard to
analysis of clinical outcome and to reduce the risk of graft
versus host disease possibly caused by contaminating T
cells.
Abstracts / Biol Blood Marrow Transplant 19 (2013) S194eS210 S197Removing co-cultured T and NK like T cells by CD3-
depletion during the expansion phase was possible and
resulted in a higher purity of NK cells (56 - 96%). The cells
retained their proliferative capacity after depletion and
expansion factors of 30-156-fold were obtained.
Flow cytometry analysis revealed comparable expression
of CD16, NKp30, NKp46 and NKG2D for manually or auto-
matically expanded NK cells either from CD3-depleted or
undepleted cultures.
Results show that large scale automation of NK cell
expansion is possible by use of the CliniMACS Prodigy. CD3
depletion of unwanted T and NK like T cells during culture is
feasible.170
Human Di-Chimeric Cells a New Approach for Tolerance
Inducing Protocols in Transplantation: A Preliminary
Study
Joanna Cwykiel 1, Medhat Askar 2, Maria Siemionow 3. 1 Plastic
Surgery, Cleveland Clinic, Cleveland, OH; 2 Transplant Center,
Cleveland Clinic, Cleveland, OH; 3 Cleveland Clinic Foundation,
Cleveland, OH
Background: Successful vascularized composite allograft
(VCA) transplantation requires life-long treatment
combining more than two immunosuppressive agents and
pose signiﬁcant risks and side effects. Cell based therapies
are a new promising approach for tolerance induction that
could prevent or reduce negative impact of life-long immu-
nosuppression. Bone marrow transplantation has already
been tested for solid organs, face and upper extremity
transplants for modulation of immune responses. We
propose a new cellular therapy based on the ex vivo created
donor-recipient chimeric cells as an alternative approach to
bone marrow based therapies in support of VCA. The aim of
this preclinical study was to create and characterize in vitro
the phenotype, genotype and viability of fused human di-
chimeric cells (dCC).
Materials and Methods: Fourteen ex vivo fusions of human
umbilical cord blood (UCB) cells were performed. Mono-
nuclear cells (MNCs) were isolated from UCB originating
from 2 different donors. Next MNCs were stained separately
by PKH26 and PKH67. Fusion procedure was performed
using polyethylene glycol (PEG) technique. Double PKH26
and PKH67 stained cells were sorted out and subjected to
further assessments. Flow cytometry (FC), (CD3, CD4, CD8,
CD19, CD34 and CD90, viability test), confocal microscopy
(CM), ﬂuorescent lymphocytotoxicity assay (LCT), PCR-
reverse sequence-speciﬁc oligonucleotide probe (PCR-
rSSOP) and short tandem repeat- PCR (STR-PCR) and
colony- forming unit (CFU) assay were assessed to charac-
terize the phenotype and genotype of fused human
chimeric cells.
Results: FC and CM analysis conﬁrmed UCB fusion and
creation of human dCC. Using LCT assay we determined that
human dCC are sharing HLA class I and class II antigens
speciﬁc for both types of UCB donors used for fusion. Results
of the LCT test were conﬁrmed by rSSOP and STR assaywhich
revealed that fused dCC were in fact originating (39-51%)
from each of the UCB donors. After fusion 96-99% of cells
were viable. Preliminary phenotype characterization showed
expression of all assessed markers on the surface of dCC. CFU
assay conﬁrmed the presence and functionality of dCC
mature progenitor comparable to untreated cord blood
progenitor cells.Conclusions: We successfully conﬁrmed feasibility of ex
vivo fusion of UBC cells leading to creation of human
fused dCC. We characterized cell phenotype and viability.
This unique concept of di-chimeric cell therapy introduces
new applications in transplant surgery. The ultimate goal
is to induce tolerance in VCA transplants.171
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Myeloma
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To date, despite recent progress in the treatment of
Plasma Cell Myeloma (PCM), it remains an incurable
disease in which prolonged therapy (maintenance)
appears to be beneﬁcial. Th1 immunity is critical in tumor
immune surveillance and immune mediated tumor eradi-
cation, in particular of PCM. Immune reconstitution deﬁ-
ciency following autologous stem cell transplantation
(AHCT) is believed to be a barrier to tumor eradication.
Immunotherapy efforts and attempts to boost immunity
with adoptive cell transfer have been thwarted by the
short life span of the transferred cells. In our pre-clinical
work, we found that human Th1/Tc1 lymphocytes, gener-
ated ex vivo in the presence of rapamycin (“T1.R”), pro-
longed engraftment in a human-into-murine model of
xenogeneic GVHD. Based on these data, we have imple-
mented a phase I, dose escalation clinical trial to evaluate
the feasibility and toxicity of the adoptive transfer of
autologous T1.R lymphocytes following AHCT in subjects
with recurrent or newly diagnosed high-risk PCM.
Subjects are receiving T1.R cells at doses ranging from
1x105 to 45x106 cells/kg. To generate T1.R cells, lympho-
cytes are collected by steady-state apheresis prior to
hematopoietic progenitor cell mobilization/collection;
elutriated lymphocytes are then cultured for 6 days using
CD3, CD28 co-stimulation, polarizing cytokines (IL-2 + IFN-
alpha), and high-dose rapamycin (1 mmol) and adminis-
tered 6-8 weeks following AHCT. T1.R cells were generated
in all cases (n¼13); eight subjects have safely received
T1.R cells at a median of 55 days post-AHCT. There have
been no clinical adverse events attributable to the T1.R
cells, and there has been no post-infusion serum elevation
of the following cytokines tested at 1h, 4h, 24h, 48h, 72h
and 7, 14 and 28 days: GM-CSF, INF-g, IL-1b, IL-6, IL-8 and
TNF-a. Current accrual is proceeding at the 5 x 106 cells/
kg cohort. T1.R cell recipients have in general shown
a disease response (see Table), although the median post-
